uniQure (NASDAQ:QURE) Shares Down 5.1% – Here’s What Happened

05 Dec 2025, 14:16 by Doug Wharley · The Cerbat Gem

uniQure N.V. (NASDAQ:QURE – Get Free Report)’s stock price traded down 5.1% during trading on Friday . The company traded as low as $21.47 and last traded at $21.5790. 807,901 shares changed hands during trading, a decline of 64% from the average session volume of 2,242,114 shares. The stock had previously closed at $22.74.

Analyst Upgrades and Downgrades

QURE has been the subject of a number of analyst reports. HC Wainwright lowered their target price on shares of uniQure from $110.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday, November 4th. UBS Group set a $95.00 price objective on shares of uniQure in a report on Thursday, September 25th. Stifel Nicolaus lifted their target price on uniQure from $30.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Wells Fargo & Company reduced their price objective on shares of uniQure from $80.00 to $60.00 and set an “overweight” rating for the company in a research report on Wednesday, November 12th. Finally, Chardan Capital reiterated a “buy” rating and set a $53.00 target price on shares of uniQure in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $64.42.

Read Our Latest Stock Report on QURE

uniQure Stock Performance

The company has a debt-to-equity ratio of 0.23, a current ratio of 7.12 and a quick ratio of 7.12. The business has a 50 day moving average price of $45.23 and a two-hundred day moving average price of $26.05. The stock has a market cap of $1.30 billion, a PE ratio of -4.77 and a beta of 0.59.

uniQure (NASDAQ:QURE – Get Free Report) last issued its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.53). The business had revenue of $3.70 million during the quarter, compared to the consensus estimate of $4.46 million. uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%. As a group, equities research analysts forecast that uniQure N.V. will post -3.75 EPS for the current fiscal year.

Insider Activity at uniQure

In other uniQure news, Director Robert Gut sold 31,434 shares of the firm’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $27.26, for a total value of $856,890.84. Following the completion of the sale, the director owned 40,145 shares of the company’s stock, valued at $1,094,352.70. This trade represents a 43.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Christian Klemt sold 15,000 shares of the business’s stock in a transaction on Friday, September 26th. The shares were sold at an average price of $55.00, for a total transaction of $825,000.00. Following the sale, the chief financial officer directly owned 217,730 shares of the company’s stock, valued at $11,975,150. This represents a 6.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 314,560 shares of company stock worth $12,362,568 in the last three months. 4.79% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On uniQure

Several institutional investors have recently bought and sold shares of the company. Private Trust Co. NA bought a new stake in shares of uniQure during the 3rd quarter worth about $28,000. Jones Financial Companies Lllp boosted its stake in uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 509 shares in the last quarter. CIBC Private Wealth Group LLC bought a new stake in shares of uniQure in the 3rd quarter worth $50,000. Knott David M Jr acquired a new stake in shares of uniQure in the third quarter valued at $117,000. Finally, Westfield Capital Management Co. LP acquired a new stake in uniQure during the third quarter valued at $223,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

About uniQure

(Get Free Report)